Prevention of ischaemic events in subjects with polydistrict vascular disease

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Chronic coronary syndrome (CCS) is associated with a high incidence of new cardiovascular events.
• Patients with CCS often have multiple thrombotic risk factors, including diabetes mellitus, renal failure, multivessel coronary artery disease, and heart failure, further increasing event risk.

Purpose of the Study:

• To outline strategies for reducing recurrent cardiovascular events in patients with chronic coronary syndrome.
• To emphasize the importance of individualized risk stratification and optimal antithrombotic therapy selection.

Main Methods:

• Individualized stratification of ischemic and hemorrhagic risk.
• Selection of appropriate antithrombotic therapy, including dual antiplatelet therapy or combination with low-dose anticoagulants.

Main Results:

• Recurrent cardiovascular events in CCS patients can be significantly reduced through targeted therapeutic strategies.
• Optimizing antithrombotic therapy, potentially combining aspirin with a second antiplatelet or a low-dose anticoagulant, maximizes net clinical benefit.

Conclusions:

• Personalized risk assessment and tailored antithrombotic treatment are crucial for managing chronic coronary syndrome.
• Combining aspirin with other antithrombotic agents offers a promising approach to improve outcomes and minimize recurrent cardiovascular events in high-risk CCS patients.